Youtube
LYKALABS

Lyka Labs Ltd.

₹141.25

Score

46

Technically Neutral

Lyka Labs Price Change Analysis

Lyka Labs Key Statistics
  • P/E Ratio

    -29.5

  • PEG Ratio

    0

  • Market Cap Cr

    405.2

  • Price to Book Ratio

    18.7

  • EPS

    -4.5

  • Dividend

    0 ()

  • Relative Strength Index

    36.55

  • Money Flow Index

    28.55

  • MACD Signal

    -3.9

  • Average True Range

    10.1

Investment Ratings

  • Master Rating:

EPS Strength

Price Strength

Buyer Demand

Group Rank

Result Highlights

Lyka Labs Synopsis

NSE-Medical-Generic Drugs

Lyka Labs is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 62.26 Cr. and Equity Capital is Rs. 28.69 Cr. for the Year ended 31/03/2021. Lyka Labs Ltd. is a Public Limited Listed company incorporated on 29/12/1976 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1976PLC008738 and registration number is 008738.
  • Market Cap

    405.25

  • Sales

    154.49

  • Shares in Float

    1.49

  • No of Funds

    19

  • Yield

  • Book Value

    87.37

  • U/D Vol Ratio

    0.9

  • LTDebt/Equity

    3410

  • Alpha

    0.44

  • Beta

    0.75

Lyka Labs Ownership
Lyka Labs Management

Lyka Labs Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Eps And Sales Estimates

Lyka Labs Financials

Lyka Labs Technicals

EMA & SMA

CURRENT PRICE

EMA

Lyka Labs Resistance and Support

Lyka Labs Delivery and Volume

Lyka Labs Price Change Analysis

Corporate Action

MF Shareholding

Similar Stocks

Videos

About Company

News

FAQs

Lyka Labs share price is

Open Demat Account